Enanta

Rendered image of a respiratory syncytial virus

Biotech

Enanta RSV antiviral reduces viral load in ph. 2 pediatric trial

Enanta’s zelicapavir reduced viral load in children, maintaining hopes the biotech can find a niche in a market dominated by Big Pharma vaccines.

James Waldron Dec 9, 2024 9:35am

RSV virus

Enanta's RSV antiviral crushes viral load in challenge study

Sep 26, 2024 7:43am

RSV virus

Enanta halts work on joint hMPV-RSV drug to extend cash to 2027

Nov 21, 2023 8:30am

covid test negative test tube COVID-19 pandemic

Enanta makes the case for COVID-19 antiviral's mixed data

May 9, 2023 9:47am

Where are they now? Tracking down 2012's Fierce 15

Aug 29, 2022 3:00am

Enanta Pharmaceuticals CEO Jay Luly

Enanta sinks to multiyear low as phase 2b RSV trial flames out

May 19, 2022 8:47am